Business Wire1mon
Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-002 for the Treatment of Danon Disease
SAN DIEGO--(BUSINESS WIRE)--Papillon Therapeutics Inc., a clinical ... including tax credits toward the cost of clinical trials and waivers on prescription drug user fees. About PPL-002 PPL ...